ImmunovantIMVT
IMVT
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
305% more call options, than puts
Call options by funds: $73.9M | Put options by funds: $18.2M
34% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 29
12% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 60
2% more funds holding
Funds holding: 181 [Q3] → 185 (+4) [Q4]
2.01% more ownership
Funds ownership: 54.06% [Q3] → 56.06% (+2.01%) [Q4]
10% less capital invested
Capital invested by funds: $2.26B [Q3] → $2.04B (-$218M) [Q4]
14% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 6 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$33
93%
upside
Avg. target
$42
146%
upside
High target
$51
198%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Jason Gerberry 0% 1-year accuracy 0 / 2 met price target | 93%upside $33 | Buy Maintained | 20 Mar 2025 |
HC Wainwright & Co. Douglas Tsao 23% 1-year accuracy 39 / 167 met price target | 198%upside $51 | Buy Reiterated | 19 Mar 2025 |
Financial journalist opinion
Based on 7 articles about IMVT published over the past 30 days
Positive
Zacks Investment Research
1 week ago
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
Positive
Seeking Alpha
1 week ago
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoclimab in phase 2b study targeting patients with Chronic Inflammatory Demyelinating Polyneuropathy; IgG was reduced by ≥ 70%. Data from both phase 3 studies, using batoclimab to treat patients with Active Thyroid Eye Disease, expected 2nd half of 2025.
Neutral
PRNewsWire
1 week ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
NEW YORK , March 19, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant's directors breached their fiduciary duties in connection with recent corporate actions.
Positive
Investors Business Daily
1 week ago
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
Positive
Reuters
1 week ago
Immunovant's muscle disorder treatment meets main goal in late-stage trial
Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.
Neutral
GlobeNewsWire
1 week ago
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
Neutral
GlobeNewsWire
1 week ago
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
Negative
Zacks Investment Research
1 month ago
Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Immunovant (IMVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Negative
Zacks Investment Research
1 month ago
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
Neutral
GlobeNewsWire
1 month ago
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal third quarter ended December 31, 2024.
Charts implemented using Lightweight Charts™